CN101466717A - 噻唑基-二氢-吲唑 - Google Patents

噻唑基-二氢-吲唑 Download PDF

Info

Publication number
CN101466717A
CN101466717A CNA200780021166XA CN200780021166A CN101466717A CN 101466717 A CN101466717 A CN 101466717A CN A200780021166X A CNA200780021166X A CN A200780021166XA CN 200780021166 A CN200780021166 A CN 200780021166A CN 101466717 A CN101466717 A CN 101466717A
Authority
CN
China
Prior art keywords
alkyl
group
cycloalkyl
thiazolinyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200780021166XA
Other languages
English (en)
Chinese (zh)
Inventor
马赛厄斯·格劳尔特
尤多·梅尔
马赛厄斯·霍夫曼
斯蒂芬·朔伊勒
安妮·T·乔尔根森
亚历山大·波奇
特里克西·布兰德尔
克里斯托夫·霍恩科
斯蒂芬·布雷特费尔德
克劳斯·厄尔布
迈克尔·皮珀
英戈·普拉格斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36763499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101466717(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN101466717A publication Critical patent/CN101466717A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA200780021166XA 2006-04-06 2007-03-27 噻唑基-二氢-吲唑 Pending CN101466717A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06112297.4 2006-04-06
EP06112297 2006-04-06

Publications (1)

Publication Number Publication Date
CN101466717A true CN101466717A (zh) 2009-06-24

Family

ID=36763499

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200780021166XA Pending CN101466717A (zh) 2006-04-06 2007-03-27 噻唑基-二氢-吲唑

Country Status (15)

Country Link
US (2) US20070238718A1 (cg-RX-API-DMAC7.html)
EP (1) EP2018387A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009532417A (cg-RX-API-DMAC7.html)
KR (1) KR20090026129A (cg-RX-API-DMAC7.html)
CN (1) CN101466717A (cg-RX-API-DMAC7.html)
AR (1) AR060266A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007236047A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0709743A2 (cg-RX-API-DMAC7.html)
CA (1) CA2647295A1 (cg-RX-API-DMAC7.html)
IL (1) IL194496A0 (cg-RX-API-DMAC7.html)
MX (1) MX2008012539A (cg-RX-API-DMAC7.html)
RU (1) RU2008143557A (cg-RX-API-DMAC7.html)
TW (1) TW200806680A (cg-RX-API-DMAC7.html)
WO (1) WO2007115933A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200807821B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007108936A2 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
CA2649913A1 (en) 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
AR066721A1 (es) * 2007-05-24 2009-09-09 Wyeth Corp Derivados de benzo[d]imidazol-1-il, composicion farmaceutica, proceso de preparacion y uso.
CA2693138A1 (en) 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
PE20091617A1 (es) * 2008-03-13 2009-11-12 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US20110230472A1 (en) * 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
EP2421872B1 (en) * 2009-04-22 2015-06-10 Boehringer Ingelheim International GmbH Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
TWI423980B (zh) * 2009-09-28 2014-01-21 Hoffmann La Roche 苯并氧氮呯pi3k抑制劑化合物及使用方法
EP2970217B1 (en) 2013-03-15 2017-08-09 Idorsia Pharmaceuticals Ltd Novel acrylamide derivatives as antimalarial agents
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
JP2022515256A (ja) 2018-12-25 2022-02-17 ソル - ゲル テクノロジーズ リミテッド Egfr阻害剤を含む組成物による皮膚障害の治療
TWI839652B (zh) * 2020-10-28 2024-04-21 日商鹽野義製藥股份有限公司 具有抗病毒活性的醯胺衍生物
JP7454729B2 (ja) * 2022-04-27 2024-03-22 塩野義製薬株式会社 抗ウイルス活性を有するアミド誘導体を含有する医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
PL357099A1 (en) * 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
UY29149A1 (es) * 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US7691888B2 (en) * 2004-10-07 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazole

Also Published As

Publication number Publication date
RU2008143557A (ru) 2010-06-20
AU2007236047A1 (en) 2007-10-18
EP2018387A1 (de) 2009-01-28
CA2647295A1 (en) 2007-10-18
WO2007115933A1 (de) 2007-10-18
AR060266A1 (es) 2008-06-04
IL194496A0 (en) 2009-08-03
US20070238718A1 (en) 2007-10-11
MX2008012539A (es) 2008-10-10
US20090093474A1 (en) 2009-04-09
BRPI0709743A2 (pt) 2011-07-26
TW200806680A (en) 2008-02-01
ZA200807821B (en) 2009-08-26
KR20090026129A (ko) 2009-03-11
JP2009532417A (ja) 2009-09-10

Similar Documents

Publication Publication Date Title
CN101460508A (zh) 噻唑基-二氢-喹唑啉
CN101460507A (zh) 噻唑基-二氢-吲唑
TWI421077B (zh) 經取代哌啶-二氫噻吩并嘧啶
US7511045B2 (en) Compounds for the treatment of inflammatory diseases
JP5122287B2 (ja) Pi3キナーゼ
CN101460167A (zh) 用作pi3-激酶抑制剂的噻唑基-二氢-环戊二烯并吡唑
TW200806680A (en) Thiazolyl-dihydro-indazole
CN101426505A (zh) 用于治疗炎性疾病的二氢噻吩并嘧啶
CN101460505B (zh) 噻唑基-二氢-喹唑啉
JP5484072B2 (ja) Pi3−キナーゼインヒビターとしてのプテリジノン誘導体
US8173699B2 (en) Compounds for the treatment of inflammatory diseases
JP5080450B2 (ja) 新規なピペリジン置換インドール
CN101166723A (zh) 用于治疗炎性疾病的新颖化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090624